Skip to main content

Articles

160 result(s) within Volume 11 of Radiation Oncology

Page 4 of 4

  1. The aim of this study is to evaluate the radiobiological impact of Acuros XB (AXB) vs. Anisotropic Analytic Algorithm (AAA) dose calculation algorithms in combined dose-volume and biological optimized IMRT pla...

    Authors: X. Liang, J. Penagaricano, D. Zheng, S. Morrill, X. Zhang, P. Corry, R. J. Griffin, E. Y. Han, M. Hardee and V. Ratanatharathom
    Citation: Radiation Oncology 2016 11:10
  2. A new entity of patients with recurrent prostate cancer limited to a small number of active metastatic lesions is having growing interest: the oligometastatic patients. Patients with oligometastatic disease co...

    Authors: Francesco Pasqualetti, Marco Panichi, Aldo Sainato, Fabrizio Matteucci, Luca Galli, Paola Cocuzza, Patrizia Ferrazza, Gabriele Coraggio, Giuseppe Pasqualetti, Lisa Derosa, Martina Sollini, Lorenzo Mannelli, Simona Ortori, Fabio Monzani, Sergio Ricci, Carlo Greco…
    Citation: Radiation Oncology 2016 11:9
  3. Treatment of intermediate and high-risk prostate cancer with a high BED has been shown to increase recurrence free survival (RFS). While high dose rate (HDR) brachytherapy, given as a boost is effective in del...

    Authors: Mekhail Anwar, Vivian Weinberg, Zachary Seymour, I. Joe Hsu, Mack Roach III and Alex R. Gottschalk
    Citation: Radiation Oncology 2016 11:8
  4. The EORTC has launched a phase II trial to assess safety and efficacy of SBRT for centrally located NSCLC: The EORTC 22113-08113—Lungtech trial. Due to neighbouring critical structures, these tumours remain ch...

    Authors: Marie Lambrecht, Christos Melidis, Jan-Jakob Sonke, Sonja Adebahr, Ronald Boellaard, Marcel Verheij, Matthias Guckenberger, Ursula Nestle and Coen Hurkmans
    Citation: Radiation Oncology 2016 11:7
  5. After the failure of first-line treatment, the clinical prognosis in head and neck cancer (HNSCC) deteriorates. Effective therapeutic strategies are limited due to the toxicity of previous treatments and the d...

    Authors: M. Ritter, I. U. Teudt, J. E. Meyer, U. Schröder, G. Kovács and B. Wollenberg
    Citation: Radiation Oncology 2016 11:6
  6. To evaluate clinical outcomes of stereotactic body radiotherapy (SBRT) for localized primary and oligometastatic lung tumors by assessing efficacy and safety of 5 regimens of varying fraction size and number.

    Authors: Masahiko Aoki, Yoshiomi Hatayama, Hideo Kawaguchi, Katsumi Hirose, Mariko Sato, Hiroyoshi Akimoto, Ichitaro Fujioka, Shuichi Ono, Eiki Tsushima and Yoshihiro Takai
    Citation: Radiation Oncology 2016 11:5
  7. Standard chemoradiotherapy (CRT) using cisplatin (CDDP) and 5-fluorouracil (5-FU) is an optional treatment for patients with stage II-III esophageal cancer. However, there are some demerits in this regimen bec...

    Authors: Hideomi Yamashita, Akihiro Haga, Ryousuke Takenaka, Tomoki Kiritoshi, Kae Okuma, Kuni Ohtomo and Keiichi Nakagawa
    Citation: Radiation Oncology 2016 11:4
  8. Hypofractionated three-dimensional conformal radiation therapy (3D-CRT) is a treatment option for patients with early-stage non-small cell lung cancer (NSCLC) who are medically unable to tolerate surgery and w...

    Authors: Masakuni Sakaguchi, Toshiya Maebayashi, Takuya Aizawa, Naoya Ishibashi, Shoko Fukushima, Osamu Abe and Tsutomu Saito
    Citation: Radiation Oncology 2016 11:3
  9. To verify the accuracy of volumetric arc therapy (VMAT) using the RapidArcâ„¢ device when switching patients from one single linear accelerator (linac) to a paired energy and mechanics "twin" linac without reopt...

    Authors: P. Fenoglietto, M. Khodri, D. Nguyen, F. Josserand-Pietri and N. Aillères
    Citation: Radiation Oncology 2016 11:2
  10. The present study aimed to define the optimal number of atlases for automatic multi-atlas-based brachial plexus (BP) segmentation and to compare Simultaneous Truth and Performance Level Estimation (STAPLE) lab...

    Authors: Joris Van de Velde, Johan Wouters, Tom Vercauteren, Werner De Gersem, Eric Achten, Wilfried De Neve and Tom Van Hoof
    Citation: Radiation Oncology 2016 11:1

Annual Journal Metrics

  • 2022 Citation Impact
    3.6 - 2-year Impact Factor
    3.8 - 5-year Impact Factor
    1.370 - SNIP (Source Normalized Impact per Paper)
    1.037 - SJR (SCImago Journal Rank)

    2023 Speed
    16 days submission to first editorial decision for all manuscripts (Median)
    132 days submission to accept (Median)

    2023 Usage 
    1,958,690 downloads
    605 Altmetric mentions